Document:

Exhibit 10.2

 

WARRANT

 

THESE SECURITIES AND THE SECURITIES
ISSUABLE UPON THEIR EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND MAY NOT BE TRANSFERRED UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, A “NO-ACTION”
LETTER FROM THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION” OR THE “SEC”)
WITH RESPECT TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE COMMISSION, OR AN OPINION OF COUNSEL SATISFACTORY
TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

MassRoots, Inc.

 

WARRANT NO. JULY 2019 1-__

 

Issuance Date: July __, 2019

 

MassRoots, Inc., a corporation
organized under the laws of the State of Delaware (the “Company”), hereby certifies that, for value received,
____________ or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter, to purchase from the Company up to a total of twenty five thousand (25,000) shares of the common
stock, $0.001 par value per share (the “Common Stock”), of the Company (the “Warrant Shares”),
at an exercise price equal to seven and one-half cents ($0.075) per share (the “Exercise Price”). Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in that certain Certificate of Designation for Series
B Preferred Stock filed on July ___, 2019 (the “COD”).This warrant (“Warrant”) may be exercised
any time after the Issuance Date through and including the third (3rd) anniversary of the Issuance Date (the “Expiration
Date”), subject to the following terms and conditions:

 

1. Registration
of Warrant. The Company shall, from time to time and whenever requested by the Holder, register this Warrant in conformity
with records to be maintained by the Company for such purpose (the “Warrant Register”) in the name of the Holder.
The Company shall treat the registered Holder of this Warrant as the absolute owner hereof for any and all purposes, including
the exercise hereof or any distribution to the Holder, and the Company shall not be affected by notice to the contrary.

 

2. Registration
of Transfers and Exchanges.

 

(a) The Company or the
transfer agent shall enter or record the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender
of this Warrant to the Company at the office specified herein or pursuant to Section 11 hereof. Upon any such registration
or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant hereinafter
referred to as a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the
transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the
Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of
the rights and obligations of a holder of a Warrant.

 

    -1-

     

    

 

(b) This Warrant is
exchangeable, upon the surrender hereof by the Holder to the office of the Company specified herein or pursuant to Section
3(b) hereof for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which
may then be purchased hereunder. Any such New Warrant shall be dated as of the Issuance Date.

 

(c) This Warrant may
be offered for sale, sold, transferred or assigned without the consent of the Company in accordance with an exemption from registration
under the Securities Act of 1933 (the “Securities Act”) including what is referred to as Section 4(a)(11⁄2)
and/or 4(a)(7) and applicable state securities laws.

 

3. Duration and
Exercise of Warrants.

 

(a) This Warrant shall
be exercisable by the registered Holder on any business day before 5:00 P.M., Eastern time, at any time and from time to time
on or after the Issuance Date to and including the Expiration Date. At 4:59 P.M., Eastern time on the Expiration Date, the portion
of this Warrant not exercised prior thereto shall be automatically exercised on a cashless basis under Section 8(b) and
become void and of no value. Prior to the Expiration Date, the Company may not call or otherwise redeem this Warrant without the
prior written consent of the Holder, which consent shall be given or withheld at the sole and absolute discretion of the Holder.

 

(b) Subject to Section
2(b), Section 5 and Section 9 hereof, upon: (x) providing the Form of Election to Purchase, attached hereto
as Exhibit A (the “Notice of Election”), duly completed and signed, to the Company at its address
for notice set forth in Section 10 hereof; and (y) payment of the Exercise Price multiplied by the number of Warrant Shares
that the Holder intends to purchase hereunder, in the manner provided hereunder, all as specified by the Holder in the Form of
Election to Purchase, the Company shall promptly (but in no event later than two business days after the Date of Exercise (as
defined below)) issue or cause to be issued and cause to be delivered to the Holder in such name(s) as the Holder may designate,
a certificate for the Warrant Shares issuable upon such exercise and free of restrictive legends unless (i) a registration statement
covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the
Warrant Shares are not freely transferable pursuant to Rule 144 (including without volume restrictions pursuant to Rule 144) promulgated
under the Securities Act, then the Warrant Shares will bear a Securities Act restrictive legend, or (ii) this Warrant shall have
been issued pursuant to a written agreement between the original Holder and the Company, as required by such agreement. Any person
so designated by the Holder to receive Warrant Shares shall be deemed to have become holder of record of such Warrant Shares as
of the Date of Exercise of this Warrant. A “Date of Exercise” means the date on which the Company shall have
received (I) if exercised in full, this Warrant (or any New Warrant, as applicable), together with the Form of Election to Purchase
attached hereto (or attached to such New Warrant) appropriately completed and duly signed; and (II) payment of the Exercise Price
for the number of Warrant Shares so indicated by the holder hereof to be purchased. Notwithstanding anything herein to the contrary
(although the Holder may surrender the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not
be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for
cancellation within two business days of the date the Form of Election is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of
lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases.

 

    -2-

     

    

 

(c) This Warrant shall
be exercisable in its entirety or, from time to time, for a portion of the number of Warrant Shares. In the event the Common Stock
representing the Warrant Shares is not delivered per the written instructions of the Holder within two business days after the
Notice of Election and Warrant is received by the Company (the “Delivery Date”), then the Company shall pay
to Holder in cash 2.0% of the dollar value of the Warrant Shares to be issued for the first day after the Delivery Date that the
Warrant Shares are not delivered, and an additional 2.0% of the dollar value of the Warrant Shares to be issued after the Delivery
Date for every 30 days thereafter that the Warrant Shares are not delivered. If any period is less than 30 days, the payment shall
be pro-rated. The Company acknowledges that its failure to deliver the Warrant Shares by the Delivery Date will cause the Holder
to suffer damages in an amount that will be difficult to ascertain. Accordingly, the parties hereto agree that it is appropriate
to include in this Warrant this provision for liquidated damages. The parties hereto acknowledge and agree that the liquidated
damages provision set forth in this section represents the parties’ good faith effort to quantify such damages and therefore
agree that the form and amount of such liquidated damages are reasonable and will not constitute a penalty. Notwithstanding the
foregoing, the payment of liquidated damages shall not relieve the Company from its obligations to deliver the Warrant Shares
pursuant to the terms of this Warrant. The Company shall make any payments incurred under this Section 3 in immediately
available funds within five business days from the date the Warrant Shares should have been delivered and each 30 day period thereafter.
Nothing herein shall limit Holder’s right to pursue actual damages or cancel the Notice of Election for the Company’s
failure to issue and deliver Warrant Shares. For the purposes of this Section 3(c), the “dollar value” of the
Warrant Shares shall be the closing price of the Company’s common stock on the Delivery Date.

 

4. Payment of Taxes.
Upon the exercise of this Warrant, the Company will pay all documentary stamp taxes attributable to the issuance of Warrant Shares;
provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved
in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall
be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant
Shares upon exercise hereof.

 

5. Replacement
of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon
receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and indemnity, if requested, satisfactory
to it. Applicants for a New Warrant under such circumstances shall comply with such other reasonable regulations and procedures
and pay such other reasonable charges as the Company may prescribe. The Holder shall not be required to post a bond or other security.

 

    -3-

     

    

 

6. Reservation
of Warrant Shares.

 

(a) The Company covenants
that it will reserve from its authorized and unissued Common Stock, solely for the purpose of the exercise of this Warrant, no
less than 100% of such aggregate maximum number of Warrant Shares then issuable upon the exercise of this Warrant (the “Required
Reserve Amount”). The Company further covenants that its issuance of this Warrant shall constitute full authority to
its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued
as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which
the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase
rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).

 

(b) If, at any time
while this Warrant remains outstanding, the Company does not have a sufficient number of authorized and unreserved shares of Common
Stock to satisfy its obligation to reserve the Required Reserve Amount (an “Authorized Share Failure”), then
the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock to an
amount sufficient to allow the Company to reserve the Required Reserve Amount for all the Warrants then outstanding. Without limiting
the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure,
but in no event later than 75 days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of
its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting,
the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’
approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders
that they approve such proposal. In lieu of holding a meeting of stockholders, the Company may take such action by consent of
its stockholders by the above date in compliance with Section 14(c) of the Securities Exchange Act of 1934 (the “Exchange
Act”). After the 75 day cure period provided for in this Section 6(b), upon the occurance of an Authorized Share Failure,
the liquidated damages provided for in Section 3(c) shall apply with payments due each 30 days.

 

    -4-

     

    

 

(c) Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use best efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

(d) Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof.

 

7. Certain Adjustments.

 

(a) Stock Dividends
and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a
distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the total consideration required to exercise this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
7(a) shall become effective immediately upon the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately upon the effective date in the case of a subdivision, combination
or re-classification.

 

    -5-

     

    

 

(b) Subsequent Equity
Sales. For a period of two years from the Issuance Date, in the event that the Company shall, at any time, issue or sell any
additional shares of Common Stock or Common Stock Equivalents (hereafter defined) (“Additional Shares of Common Stock”),
in a transaction other than an Exempt Issuance, at a price per share less than the Exercise Price then in effect or without consideration
(a “Dilutive Issuance” based on a “Dilutive Issuance Price”), then the Exercise Price upon
each such issuance shall be reduced to the Dilutive Issuance Price, and the number of Warrant Shares (excluding Warrant Shares
previously exercised) shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying
the Exercise Price then in effect immediately prior to such adjustment by the number of Warrant Shares (excluding Warrant Shares
previously exercised) acquirable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof
by the Exercise Price resulting from such adjustment. By way of example, if E is the total number of Warrant Shares in effect
immediately prior to such Dilutive Issuance, F is the Exercise Price in effect immediately prior to such Dilutive Issuance, and
G is the Dilutive Issuance Price, the adjustment to the number of Warrant Shares can be expressed in the following formula: Total
number of Warrant Shares after such Dilutive Issuance = the quotient obtained from dividing [E x F] by G. “Exempt Issuance”
means the issuance of Common Stock pursuant to an exercise of this Warrant. “Common Stock Equivalents” means
any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

If the price per share
for which Additional Shares of Common Stock are sold, or may be issuable pursuant to any such Common Stock Equivalent, is less
than the applicable Exercise Price then in effect, or if, after any such issuance of Common Stock Equivalents, the price per share
for which Additional Shares of Common Stock may be issuable thereafter is amended or adjusted, and such price as so amended shall
be less than the applicable Exercise Price in effect at the time of such amendment or adjustment, then the applicable Exercise
Price and number of Warrant Shares shall be adjusted upon each such issuance or amendment as provided in this Section 7(b).
In case any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company, together
comprising one integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for the Option Value
of such Common Stock Equivalents and (y) the other securities issued or sold in such integrated transaction shall be deemed to
have been issued or sold for the difference of (I) the aggregate consideration received by the Company less any consideration
paid or payable by the Company pursuant to the terms of such other securities of the Company, less (II) the Option Value. If any
shares of Common Stock or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the amount
of such consideration received by the Company will be deemed to be the net amount received by the Company therefor. If any shares
of Common Stock or Common Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration
received by the Company will be the fair value of such consideration, except where such consideration consists of publicly traded
securities, in which case the amount of consideration received by the Company will be the VWAP of such public traded securities
on the date of receipt. If any shares of Common Stock or Common Stock Equivalents are issued to the owners of the non-surviving
entity in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be
deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such
shares of Common Stock or Common Stock Equivalents, as the case may be.

 

    -6-

     

    

 

“Option Value” means the value
of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the “OV” function on Bloomberg
L.P. determined as of (A) the Trading Day prior to the public announcement of the issuance of the applicable Common Stock Equivalent,
if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance
of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, for pricing
purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining
term of the applicable Common Stock Equivalent as of the applicable date of determination, (ii) an expected volatility equal to
the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg L.P. as of (A) the Trading Day immediately
following the public announcement of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is
publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if the
issuance of such Common Stock Equivalent is not publicly announced, (iii) the underlying price per share used in such calculation
shall be the highest VWAP of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive
documentation relating to the issuance of the applicable Common Stock Equivalent and ending on (A) the Trading Day immediately
following the public announcement of such issuance, if the issuance of such Common Stock Equivalent is publicly announced or (B)
the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock
Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.

 

“VWAP” means, for any date,
the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a
Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink
Sheets” published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the
Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

The provisions of this Section 7(b)
shall apply each time the Company, at any time after the Issuance Date and prior to the date that is two years from Original
Issuance Date, shall issue any securities with a Dilutive Issuance Price.  

 

(c) Voluntary Adjustment
By Company. The Company may at any time during the term of this Warrant, reduce the then current Exercise Price to any amount
and for any period of time deemed appropriate by the board of directors of the Company.

 

    -7-

     

    

 

(d) Notice; Variable
Rate Transactions. The Company shall notify the Holder, in writing, no later than the business day following the issuance
or deemed issuance of any Common Stock or Common Stock Equivalents subject to Section 7(b), indicating therein the applicable
issuance price, or applicable reset price, exchange price, conversion price and other pricing terms. If the Company enters into
a Variable Rate Transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest
possible conversion or exercise price at which such securities may be converted or exercised and the Exercise Price shall be adjusted
for the Dilutive Issuance. Variable Rate Transaction means: a transaction in which the Company
(i) issues or sells any Common Stock Equivalents either (A) at a conversion, exercise or exchange rate or other price that is
based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future
date after the initial issuance of such securities or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock, or (ii) enters into any agreement (including, but not
limited to, an equity line of credit) whereby the Company may sell securities at a future determined price (other than customary
“pre-emptive” or “participation” rights).

 

(e) Pro Rata Distributions.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its
assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time
after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to
such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

(f) Calculations.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of
a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any, issued and outstanding.

 

(g) Notice to Holder.

 

(i) Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 7, the Company
shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

    -8-

     

    

 

(ii) Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange
their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing
thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice except as may otherwise be expressly set forth herein. In addition to any other remedies provided
by this Agreement or other transaction documents, if the Company provides any material, non-public information to the Holder without
its prior written consent, and it fails to immediately (no later than that business day) file a Form 8-K disclosing this material,
non-public information, it shall pay the Holder as partial liquidated damages and not as a penalty a sum equal to $1,000 per business
day for each $50,000 of the Holder’s subscription amount for which this Warrant was issued beginning with the day the information
is disclosed to the Holder and ending and including the day the Form 8-K disclosing this information is filed.

 

    -9-

     

    

 

(h) Fundamental Transaction.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects
any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by
the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the exercise
of this Warrant), at the option of the Holder the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice
as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall,
at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental
Transaction, purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value
of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction or (ii) the
positive difference between the cash per share paid in such Fundamental Transaction minus the then in effect Exercise Price. “Black
Scholes Value” means the value of the unexercised portion of this Warrant based on the Black and Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg L.P. determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate
for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Expiration
Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg
L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying
price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value
of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Expiration Date. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section
7(h) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder
in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant prior
to such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant), and with an exercise price
which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the
shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for
(so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

    -10-

     

    

 

8. Payment of Exercise
Price. The Holder, at its sole election, may pay the Exercise Price in one of the following manners:

 

(a) Cash Exercise.
The Holder shall deliver immediately available funds; or

 

(b) Cashless Exercise.
If at any time after the six month anniversary of the Issuance Date, there is no effective Registration Statement registering,
or no current prospectus available for, the resale of the Warrant Shares issuable hereunder by the Holder, this Warrant may be
exercised by means of a cashless exercise unless an effective registration statement covers the Warrant Shares and a current prospectus
has been filed on www.sec.gov. In such event, the Holder shall surrender this Warrant to the Company, together with a notice of
cashless exercise, and the Company shall issue to the Holder the number of Warrant Shares determined as follows:

 

[(A x B) - (A x C)]
divided by (B), where:

 

A = the number of Warrant Shares
with respect to which this Warrant is being exercised.

 

B = the average closing bid price
of the Common Stock for the five trading days immediately prior to the Date of Exercise.

 

C = the Exercise Price.

 

For purposes of Section 4(a)(1) of, and
Rule 144 under, the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise
transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed
to have been commenced, on the Issuance Date.

 

    -11-

     

    

 

(c) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant to the extent that after giving effect to such issuance after exercise as set forth on the
applicable Notice of Election, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group
together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include
the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or
conversion of the unexercised or non-converted portion of any other securities of the Company (including, without limitation,
any other Common Stock equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence,
for purposes of this Section 8(c), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section
8(c) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the Holder, and the submission of a Notice of Election shall be deemed to be the Holder’s determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and
the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as
to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder. For purposes of this Section 8(c), in determining the number of outstanding shares
of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Securities and Exchange Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the transfer agent setting forth the
number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within three
trading days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported.

 

    -12-

     

    

 

The “Beneficial Ownership Limitation”
shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The limitations contained in this paragraph shall apply to a successor
holder of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase the Beneficial
Ownership Limitation provisions of this Section 8(c) solely with respect to the Holder’s Warrant, provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section 8(c) shall continue to apply. Any such increase will not be effective until the 61st day after
such notice is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this Section
8(c) solely with respect to the Holder’s Warrant at any time, which decrease shall be effectively immediately upon delivery
of notice to the Company.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. 

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

9. Fractional Shares.
The Company shall not be required to issue or cause to be issued fractional Warrant Shares upon the exercise of this Warrant.
The number of full Warrant Shares which shall be issuable upon the exercise of this Warrant shall be computed on the basis of
the aggregate number of Warrant Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share
would, except for the provisions of this Section 9, be issuable on the exercise of this Warrant, the Company shall pay
an amount in cash equal to the Exercise Price multiplied by such fraction.

 

10. Notices.
Any and all notices or other communications or deliveries hereunder (except payment) shall be in writing and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar receipted next business day delivery or by email (followed
by next business day delivery), as follows:

 

If to the Company:

 

MassRoots, Inc.

7083 Hollywood Blvd., Office 4084

Office 4084

Los Angeles, CA 90028

 

If to the Holder:

 

__________________________

__________________________

__________________________

 

Or to such other address as any of them, by notice to the other
may designate from time to time. Time shall be counted to, or from, as the case may be, the date of delivery.

 

    -13-

     

    

 

11. Warrant Agent.
The Company shall serve as warrant agent under this Warrant. Upon 30 days notice to the Holder, the Company may appoint a new
warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from
any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any
new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant
agent under this Warrant without any further action. Any such successor warrant agent shall promptly cause notice of its succession
as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown
on the Warrant Register.

 

12. Miscellaneous.

 

(a) This Warrant shall
be binding on and inure to the benefit of the parties hereto. This Warrant may be amended only in writing signed by the Company
and the Holder.

 

(b) Nothing in this
Warrant shall be construed to give to any person or corporation other than the Company and the Holder any legal or equitable right,
remedy or cause under this Warrant. This Warrant shall inure to the sole and exclusive benefit of the Company and the Holder.

 

(c) The headings herein
are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions
hereof.

 

(d) In case any one
or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and
upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(e) The Company hereby
represent and warrants to the Holder that: (i) it is voluntarily issuing this Warrant of its own freewill, (ii) it is not issuing
this Warrant under economic duress, (iii) the terms of this Warrant are reasonable and fair to the Company, and (iv) the Company
has had independent legal counsel of its own choosing review this Warrant, advise the Company with respect to this Warrant, and
represent the Company in connection with its issuance of this Warrant.

 

    -14-

     

    

 

(f) Any capitalized
term used but not defined in this Warrant shall have the meaning ascribed to it in the Subscription Agreement, of even date herewith,
by and between the Company and the Holder.

 

(g) This Warrant may
be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which
taken together shall constitute one and the same Warrant. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed)
the same with the same force and effect as if such facsimile signature were the original thereof.

 

(h) This Warrant and
the obligations of the Company hereunder shall not be assignable by the Company.

 

(i) Notwithstanding
anything in this Warrant to the contrary, the parties hereto hereby acknowledge and agree to the following: (i) the Holder makes
no representations or covenants that it will not engage in trading in the securities of the Company; (ii) the Company shall, by
the second business day following the date hereof, file a Current Report on Form 8-K disclosing the material terms of the transactions
contemplated hereby and in the other Offering Materials; (iii) the Company has not and shall not provide material non-public information
to the Holder unless prior thereto the Holder Party shall have executed a written agreement regarding the confidentiality and
use of such information; and (iv) the Company understands and confirms that the Holder will be relying on the acknowledgements
set forth in clauses (i) through (iii) above if the Holder effects any transactions in the securities of the Company.

 

(j) This Warrant does
not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof.

 

    -15-

     

    

 

(k) The remedies provided
in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other transaction
documents, at law or in equity (including a decree of specific performance and/or other injunctive relief or ensuring performance
of any obligation herein or preventing a breach of any obligation herein), and nothing herein shall limit the right of the Holder
to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Warrant. The Company
covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein.
Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall
be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation
of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees
that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other
available remedies, to specific performance and an injunction restraining any breach, without the necessity of showing economic
loss and without any bond or other security being required. The Company shall provide all information and documentation to the
Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions
of this Warrant. The issuance of shares and certificates for shares as contemplated hereby upon the exercise of this Warrant shall
be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the
Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery
of any certificate in a name other than the Holder or its agent on its behalf. If (a) this Warrant is placed in the hands of an
attorney for collection or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes
action to collect amounts due under this Warrant or to enforce the provisions of this Warrant or (b) there occurs any bankruptcy,
reorganization, receivership of the company or other proceedings affecting company creditors’ rights and involving a claim
under this Warrant, then the Company shall pay the reasonable costs incurred by the Holder for such collection, enforcement or
action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation,
attorneys’ fees and disbursements.

 

(l) Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon
the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares. 

 

13. Disputes Under
This Agreement. All disputes arising under this Warrant shall be governed by and interpreted in accordance with the laws of
the State of Delaware, without regard to principles of conflict of laws, as provided for under the Subscription Agreement for
which this Warrant was issued.

 

[Signature on Following Page]

 

    -16-

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	MassRoots, Inc. 
	 	 	 
	 	By:	 
	 	Name: 	Isaac Dietrich
	 	Title:	CEO

 

    -17-

     

    

 

EXHIBIT A

 

FORM OF ELECTION TO PURCHASE

 

MassRoots, Inc.

 

		Re:	Intention to Exercise Right to Purchase Shares of Common
Stock Under the Warrant

 

Gentlemen:

 

In accordance with
the Warrant enclosed with this Form of Election to Purchase, the undersigned hereby irrevocably elects to purchase _________________shares
of Common Stock, $0.001 par value per share, of MassRoots, Inc. and, if such Holder is not utilizing the cashless exercise provisions
set forth in the Warrant, encloses herewith $________ in cash, certified or official bank check(s), which sum represents
the aggregate Exercise Price for the number of shares of Warrant Shares to which this Form of Election to Purchase relates, together
with any applicable taxes payable by the undersigned pursuant to the Warrant. Any capitalized terms used but not defined in this
Form of Election to Purchase shall have the meaning ascribed to them in the accompanying Warrant.

 

The undersigned requests
that certificates for the shares of Common Stock issuable upon this exercise be issued in the name of:

 

	 
	(Please insert SS# or FEIN #)
	 
	(Please print name and address)

 

If the number of shares
of Common Stock issuable upon this exercise shall not be all of the shares of Common Stock which the undersigned is entitled to
purchase in accordance with the enclosed Warrant, the undersigned requests that a New Warrant evidencing the right to purchase
the shares of Common Stock not issuable pursuant to the exercise evidenced hereby be issued in the name of and delivered to:

 

	 
	(Please print name and address)
	 
	 

 

	Dated: _____________, _____	Name of Holder:
	 	 

 

	 	Signed:_______________________________
	 	Print Name:____________________________
	 	Title:_________________________________

 

(Signature must conform in all respects
to name of Holder as specified on the face of the Warrant)

 

 

-18-Exhibit 10.3

 

EXCHANGE AGREEMENT

 

This Exchange Agreement
(this “Agreement”), dated as of July [  ], 2019, is made by and among MassRoots, Inc., a Delaware corporation
(the “Company”), and each of the holders of the Exchange Securities (as defined below) signatory hereto (each
a “Holder”).

 

WHEREAS, [  ] (“[
]”), holds warrants to purchase up to [  ] shares of the Company’s common stock, $0.001 per share (the “Common
Stock”) (the “Exchange Securities”) attached hereto as Exhibit A;

 

WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended
(the “Securities Act”), the Company desires to exchange with each Holder, and each Holder desires to exchange
with the Company, the Exchange Securities held by such Holder for shares of the Company’s Series A Preferred Stock, par value
$0.0001 per share (the “Series A Preferred Stock”) in such amounts to each Holder as set forth on Schedule
I attached hereto, and with the rights, preferences, and designations set forth on Exhibit B attached hereto.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Holder, with respect to itself, agree as follows:

 

1. Terms
of the Exchange. The Company and Holder agree that each Holder will exchange the Exchange Securities held by such Holder and
will relinquish any and all other rights it may have under the Exchange Securities in exchange for the Series A Preferred Stock
owing in respect of such Exchange Securities.

 

2. Closing.
Upon satisfaction of the conditions set forth herein, a closing shall occur at the principal offices of the Company, or such other
location as the parties shall mutually agree. At closing, Holder shall deliver the Exchange Securities held by such Holder to the
Company and the Company shall deliver to such Holder the Series A Preferred Stock owing in respect of such Exchange Securities.
Upon closing, any and all obligations of the Company to Holder under the Exchange Securities shall be fully satisfied, the certificates
evidencing the Exchange Securities shall be cancelled and Holder will have no remaining rights, powers, privileges, remedies or
interests under the Exchange Securities.

 

3. Further
Assurances

 

Each party shall
do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

    -1-

     

    

 

4. Representations
and Warranties of Each Holder. Each Holder represents and warrants as of the date hereof and as of the closing to the Company
as follows:

 

a. Authorization;
Enforcement. Each Holder has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement
by each Holder and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action
on the part of each Holder and no further action is required by each Holder. This Agreement has been (or upon delivery will have
been) duly executed by each Holder and, when delivered in accordance with the terms hereof, will constitute the valid and binding
obligation of each Holder enforceable against each Holder in accordance with its terms, except: (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.

 

b. Tax Advisors.
Each Holder has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this investment
and the transactions contemplated by this Agreement. With respect to such matters, each Holder relied solely on such advisors and
not on any statements or representations of the Company or any of its agents, written or oral. Each Holder understands that it
(and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions
contemplated by this Agreement.

 

c. Information
Regarding Holder. Holder is an “accredited investor,” as such term is defined in Rule 501 of Regulation D promulgated
by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act, is experienced
in investments and business matters, has made investments of a speculative nature and has purchased securities of companies in
private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business
matters as to enable each Holder to utilize the information made available by the Company to evaluate the merits and risks of and
to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment. Holder
has the authority and is duly and legally qualified to purchase and own the Series A Preferred Stock. Holder is able to bear the
risk of such investment for an indefinite period and to afford a complete loss thereof.

 

d. Legend.
Each Holder understands that the Series A Preferred Stock will be issued pursuant to an exemption from registration or qualification
under the Securities Act and applicable state securities laws, and except as set forth below, the Series A Preferred Stock shall
bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

THESE SECURITIES AND THE SECURITIES
ISSUABLE UPON THEIR EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND MAY NOT BE TRANSFERRED UNLESS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, A “NO-ACTION”
LETTER FROM THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION” OR THE “SEC”) WITH RESPECT
TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE COMMISSION, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

    -2-

     

    

 

e. Removal of Legends. Certificates evidencing shares of Common Stock issuable upon the conversion of the Series
A Preferred Stock (the “Underlying Shares”) shall not be required to contain the legend set forth in Section
4(d) above or any other legend (i) while a registration statement covering the resale of such securities is effective under the
Securities Act, (ii) following any sale of such Series A Preferred Stock pursuant to Rule 144 (assuming the transferor is not an
affiliate of the Company), (iii) if such Series A Preferred Stock are eligible to be sold, assigned or transferred under Rule 144
and each Holder is not an affiliate of the Company (provided that each Holder provides the Company with reasonable assurances that
such Series A Preferred Stock are eligible for sale, assignment or transfer under Rule 144 which shall include an opinion of each
Holder’s counsel), (iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that
each Holder provides the Company with an opinion of counsel to each Holder, in a generally acceptable form, to the effect that
such sale, assignment or transfer of the Series A Preferred Stock (including the Underlying Securities) may be made without registration
under the applicable requirements of the Securities Act or (v) if such legend is not required under applicable requirements of
the Securities Act (including, without limitation, controlling judicial interpretations and pronouncements issued by the Commission).
If a legend is not required pursuant to the foregoing, the Company shall no later than two (2) business days following the delivery
by each Holder to the Company or the transfer agent (with notice to the Company) of a legended certificate representing such Series
A Preferred Stock (including the Underlying Securities) (endorsed or with stock powers attached, signatures guaranteed, and otherwise
in form necessary to affect the reissuance and/or transfer, if applicable), together with any other deliveries from each Holder
as may be required above in this Section 4(e), as directed by each Holder, either: (A) provided that the Company’s transfer
agent is participating in the DTC Fast Automated Securities Transfer Program, credit the aggregate number of shares of Underlying
Shares to which each Holder shall be entitled to upon conversion of the such Series A Preferred Stock held by each Holder to each
Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the
Company’s transfer agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via
reputable overnight courier) to each Holder, a certificate representing such Underlying Shares that is free from all restrictive
and other legends, registered in the name of each Holder or its designee. The Company shall be responsible for any transfer agent
fees or DTC fees with respect to any issuance of Underlying Shares in accordance herewith.

 

f. Restricted
Securities. Each Holder understands that: (i) the Series A Preferred Stock has not been and is not being registered under the
Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder, (B) each Holder shall have delivered to the Company (if requested by the Company) an opinion of counsel
to each Holder, in a form reasonably acceptable to the Company, to the effect that such Series A Preferred Stock to be sold, assigned
or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) each Holder provides
the Company with reasonable assurance that such Series A Preferred Stock can be sold, assigned or transferred pursuant to Rule
144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule 144”);
and (ii) any sale of the Series A Preferred Stock made in reliance on Rule 144 may be made only in accordance with the terms of
Rule 144, and further, if Rule 144 is not applicable, any resale of the Series A Preferred Stock under circumstances in which the
seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities
Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC promulgated
thereunder.

 

    -3-

     

    

 

5. Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties to each Holder:

 

a. Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other agreements entered into by the parties hereto in connection with the transactions contemplated
by this Agreement (collectively, the “Exchange Documents”) and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated
hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company,
the Board of Directors of the Company or the Company’s stockholders in connection therewith, including, without limitation,
the issuance of the Series A Preferred Stock have been duly authorized by the Company’s Board of Directors and no further
filing, consent, or authorization is required by the Company, its Board of Directors or its stockholders. This Agreement has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.

 

b. Organization
and Qualification. Each of the Company and its subsidiaries (the “Subsidiaries”) are entities duly organized
and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power
and authorization to own their properties and to carry on their business as now being conducted and as presently proposed to be
conducted. Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good
standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect.
As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business,
properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the
Company or any Subsidiary, individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Exchange
Documents or (iii) the authority or ability of the Company to perform any of its obligations under any of the Exchange Documents.
Other than its Subsidiaries, there is no Person (as defined below) in which the Company, directly or indirectly, owns capital stock
or holds an equity or similar interest. “Person” means an individual, a limited liability company, a partnership,
a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any governmental entity or any department
or agency thereof.

 

    -4-

     

    

 

c. No Conflict.
The execution, delivery and performance of the Exchange Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance of the Securities will not (i) result in a violation
of the Certificate of Incorporation (as defined below) or other organizational documents of the Company or any of its Subsidiaries,
any capital stock of the Company or any of its Subsidiaries or Bylaws (as defined below) of the Company or any of its Subsidiaries,
(ii) except as set forth in the SEC Documents, conflict with, or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and
the rules and regulations of The OTC Markets (the “Principal Market”) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected except, in the case
of clause (ii) or (iii) above, to the extent such violations that could not reasonably be expected to have a Material Adverse Effect.

 

d. No Consents. Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or
order of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or
any other Person in order for it to execute, deliver or perform any of its respective obligations under or contemplated by the
Exchange Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings
and registrations which the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been obtained
or effected on or prior to the date of this Agreement, and neither the Company nor any of its Subsidiaries is aware of any facts
or circumstances which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration,
application or filings contemplated by the Exchange Documents. The Company is not in violation of the requirements of the Principal
Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of the Common
Stock in the foreseeable future.

 

e. Securities
Law Exemptions. Assuming the accuracy of the representations and warranties of each Holder contained herein, the offer and
issuance by the Company of the Series A Preferred Stock is exempt from registration under the Securities Act. The offer and issuance
of the Series A Preferred Stock is exempt from registration under the Securities Act pursuant to the exemption provided by Section
3(a)(9) thereof. The Company covenants and represents to each Holder that neither the Company nor any of its Subsidiaries has received,
anticipates receiving, has any agreement to receive or has been given any promise to receive any consideration from each Holder
or any other Person in connection with the transactions contemplated by the Exchange Documents.

 

    -5-

     

    

 

f. Issuance of
Series A Preferred Stock. The issuance of the Series A Preferred Stock is duly authorized and upon issuance in accordance with
the terms of the Exchange Documents shall be validly issued, fully paid and non-assessable and free from all taxes, liens, charges
and other encumbrances with respect to the issue thereof. The issuance of shares of Common Stock upon exercise of the Series A
Preferred Stock are duly authorized and, when issued and paid for in accordance with the Series A Preferred Stock, will be duly
and validly issued, fully paid and non-assessable, free from all taxes, liens, charges and other encumbrances imposed by the Company
other than restrictions on transfer provided for in such documents.

 

g. Transfer Taxes.
As of the date of this Agreement, all share transfer or other taxes (other than income or similar taxes) which are required to
be paid in connection with the issuance of the Series A Preferred Stock to be exchanged with each Holder hereunder will be, or
will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied
with.

 

h. Equity Capitalization.
Except as disclosed in the SEC Documents (as defined below): (i) none of the Company’s or any Subsidiary’s capital
stock is subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company
or any Subsidiary; (ii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock
of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any
of its Subsidiaries is or may become bound to issue additional capital stock of the Company or any of its Subsidiaries or options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any capital stock of the Company or any of its Subsidiaries; (iii) there
are no outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing indebtedness of
the Company or any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may become bound; (iv) there are
no financing statements securing obligations in any amounts filed in connection with the Company or any of its Subsidiaries; (v)
there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of
any of their securities under the Securities Act; (vi) there are no outstanding securities or instruments of the Company or any
of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries; (vii) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered
by the issuance of the Series A Preferred Stock; (viii) neither the Company nor any Subsidiary has any stock appreciation rights
or “phantom stock” plans or agreements or any similar plan or agreement; and (ix) neither the Company nor any of its
Subsidiaries have any liabilities or obligations required to be disclosed in the in the Company’s filings with the Commission
(the “SEC Documents”) which are not so disclosed in the SEC Documents, other than those incurred in the ordinary
course of the Company’s or its Subsidiaries’ respective businesses and which, individually or in the aggregate, do
not or could not have a Material Adverse Effect. The Company has furnished to each Holder true, correct and complete copies of
the Company’s Amended and Restated Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate
of Incorporation”), and the Company’s Amended and Restated Bylaws and as in effect on the date hereof (the “Bylaws”),
and the terms of all securities convertible into, or exercisable or exchangeable for, shares of Common Stock and the material rights
of the holders thereof in respect thereto that have not been disclosed in the SEC Documents.

 

    -6-

     

    

 

(i) Shell
Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i) of the Securities
Act.

 

6. Additional
Acknowledgments. Each Holder and the Company confirm that the Company has not received any consideration for the transactions
contemplated by this Agreement. Pursuant to Rule 144 promulgated by the Commission pursuant to the Securities Act and the rules
and regulations promulgated thereunder as such Rule 144 may be amended from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same effect as such Rule 144, the holding period of the Securities tacks back
to the issue date of the Exchange Securities. The Company hereby confirms that each Holder currently is not and will not be upon
closing of this Agreement (individually or together as a group) deemed an “affiliate” as defined in Rule 144. The Company
agrees not to take a position contrary to this paragraph.

 

7. Release
by Each Holders.

 

In consideration of
the foregoing, each Holder releases and discharges Company, Company’s officers, directors, principals, control persons, past
and present employees, insurers, successors, and assigns (“Company Parties”) from all actions, cause of action,
suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements,
promises, variances, trespasses, damages, judgments, extents, executions, claims, and demands whatsoever, in law, admiralty or
equity, which against Company Parties ever had, now have or hereafter can, shall or may, have for, upon, or by reason of any matter,
cause or thing whatsoever, whether or not known or unknown, arising under the Exchange Securities. It being understood that this
Section shall be limited in all respects to only matters arising under or related to the Exchange Securities and shall under no
circumstances constitute a release, waiver or discharge with respect to the Securities or any Exchange Documents or limit each
Holder from taking action for matters with respect to the Securities or any Exchange Document or events that may arise in the future.

 

8. Miscellaneous.

 

a. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns.

 

b. Governing
Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by and construed under the laws of the State of New
York, without regard to the choice of law principles thereof. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the State of New York, City of New York for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby, and hereby irrevocably waives any objection that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    -7-

     

    

 

c. Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

d. Counterparts/Execution.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains an electronic file of an executed signature
page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or electronic file signature page (as the case may be) were an
original thereof.

 

e. Notices.
Any notice or communication permitted or required hereunder shall be in writing and shall be deemed sufficiently given if hand-delivered
or sent (i) postage prepaid by registered mail, return receipt requested, or (ii) by facsimile, to the respective parties as set
forth below, or to such other address as either party may notify the other in writing.

 

If to the Company, to:

 

MassRoots, Inc.

7083 Hollywood Blvd.,
Office 4084

Office 4084

Los Angeles, CA 90028

 

With a copy to (which
shall not constitute notice):

 

Sheppard, Mullin, Richter
& Hampton LLP

30 Rockefeller Plaza

New York, NY 10112

Attn: Andrea Cataneo, Esq.

 

If to a Holder, to the
address set forth on the signature page of such Holder.

 

    -8-

     

    

 

f. Expenses.
The parties hereto shall pay their own costs and expenses in connection herewith; provided, however, the Company shall pay a total
of $5,000 of the Holders’ legal fees within two business days of the closing of this Agreement.

 

g. Entire Agreement;
Amendments. This Agreement constitutes the entire agreement between the parties with regard to the subject matter hereof and
thereof, superseding all prior agreements or understandings, whether written or oral, between the parties. This Agreement may be
amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written
instrument signed by all parties, or, in the case of a waiver, by the party waiving compliance. Except as expressly stated herein,
no delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor
shall any waiver on the part of any party of any right, power or privilege hereunder preclude any other or future exercise of any
other right, power or privilege hereunder.

 

h. Headings.
The headings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this
Agreement.

 

i. Pledge of
Series A Preferred Stock. The Company acknowledges and agrees that the Series A Preferred Stock may be pledged by each Holder
in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Series A Preferred
Stock. The pledge of the Series A Preferred Stock shall not be deemed to be a transfer, sale or assignment of the Series A Preferred
Stock hereunder, and if any Holder effects a pledge of the New Securities held by such Holder it shall not be required to provide
the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement. The Company hereby
agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge
of the Series A Preferred Stock to such pledgee by each Holder.

 

[SIGNATURE PAGES FOLLOW]

 

    -9-

     

    

 

IN WITNESS WHEREOF, the parties have caused
this Agreement to be duly executed as of the day and year first above written.

 

	 	MASSROOTS, INC.
	 	 	 
	 	By:	 
	 	Name:	Isaac Dietrich
	 	Title:	Chief Executive Officer
	 	 	 
	 	HOLDER: 
	 	 	 
	 	[  ]	 
	 	 	 
	 	By:	 
	 	Name: 	 
	 	Title: 	 
	 	 	 
	 	Address for Notices:
	 	 	 
	 	Address for delivery of Securities:

 

    -10-

     

    

 

EXHIBIT A

 

[  ]

WARRANT

 

    -11-

     

    

 

EXHIBIT B

 

SERIES A PREFERRED STOCK 

CERTIFICATE OF DESIGNATION

 

    -12-

     

    

 

SCHEDULE I

 

	Holder	
        Shares of Common Stock convertible upon
        exercise of Warrants 

        (Being Exchanged)
	Shares of Series A Preferred Stock Exchangeable therefor
	
         

        [  ]
	
         

        [  ]
	
         

        [  ]

 

 

-13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]